Aclarion Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 15

Employees

  • Stock Symbol
  • ACON

Stock Symbol

  • Share Price
  • $1.22
  • (As of Friday Closing)

Aclarion General Information

Description

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.

Contact Information

Formerly Known As
NociMed
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 8181 Arista Place
  • Suite 100
  • Broomfield, CO 80021
  • United States
+1 (833)
Primary Industry
Other Healthcare Technology Systems
Other Industries
Diagnostic Equipment
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 8181 Arista Place
  • Suite 100
  • Broomfield, CO 80021
  • United States
+1 (833)

Aclarion Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aclarion Stock Performance

As of 20-Nov-2026, Aclarion’s stock price is $1.22. Its current market cap is $3.52M with 2.88M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.22 $1.42 $1.22 - $9.36 $3.52M 2.88M 35K -$4.61

Aclarion Financials Summary

As of 30-Sep-2026, Aclarion has a trailing 12-month revenue of $98.6K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (9,339) (8,253) 191 2,447
Revenue 99 76 46 75
EBITDA (10,397) (7,417) (6,265) (4,141)
Net Income (10,112) (7,234) (6,993) (4,911)
Total Assets 15,834 13,672 2,123 2,460
Total Debt 0 0 12 1,126
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aclarion Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aclarion‘s full profile, request access.

Request a free trial

Aclarion Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Aclarion‘s full profile, request access.

Request a free trial

Aclarion Patents

Aclarion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12788268-B2 Multi-voxel prescription for lumbar disc evaluation Active 16-Oct-2024
US-20260102075-A1 Multi-voxel prescription for lumbar disc evaluation Active 16-Oct-2024
WO-2026085148-A1 Multi-voxel prescription for lumbar disc evaluation Pending 16-Oct-2024
AU-2024307180-A1 System for machine learning and mri-based evaluation of lumbar regions Pending 26-Jun-2023
EP-4732305-A1 System for machine learning and mri-based evaluation of lumbar regions Pending 26-Jun-2023 G06T7/0014
To view Aclarion’s complete patent history, request access »

Aclarion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aclarion ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

23.65 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Health Care IT Services

Subindustry

of 50

Rank

Percentile

To view Aclarion’s complete esg history, request access »

Aclarion FAQs

  • When was Aclarion founded?

    Aclarion was founded in 2008.

  • Where is Aclarion headquartered?

    Aclarion is headquartered in Broomfield, CO.

  • What is the size of Aclarion?

    Aclarion has 15 total employees.

  • What industry is Aclarion in?

    Aclarion’s primary industry is Other Healthcare Technology Systems.

  • Is Aclarion a private or public company?

    Aclarion is a Public company.

  • What is Aclarion’s stock symbol?

    The ticker symbol for Aclarion is ACON.

  • What is the current stock price of Aclarion?

    As of 20-Nov-2026 the stock price of Aclarion is $1.22.

  • What is the current market cap of Aclarion?

    The current market capitalization of Aclarion is $3.52M.

  • What is Aclarion’s current revenue?

    The trailing twelve month revenue for Aclarion is $98.6K.

  • What is Aclarion’s annual earnings per share (EPS)?

    Aclarion’s EPS for 12 months was -$4.61.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process